8 completed, 4 unknown, 2 active not recruiting, 2 not yet recruiting. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 8, Unknown 4, Active not recruiting 2, Not yet recruiting 2, Terminated 2, Enrolling by invitation 1, Withdrawn 1 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds Non-conforming pz-cel surgical application to RDEB wounds, Additional biopsies, Pz-cel surgical application to DEB wounds - Epidermolysis Bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Phase 4 | Not yet recruiting | Abeona Therapeutics, Inc | 100 | 2026-11-01 | 2026-08-06 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns Intact fish skin graft, autograft - Partial-thickness Burn Wounds | Phase 4 | Enrolling by invitation | Kerecis Ltd. | 65 | 2026-06-01 | 2026-11-12 |
| Curcumin-Based Photodynamic Therapy in Epidermolysis Bullosa: Wound Healing, Quality of Life, and Salivary Biomarkers Curcumin-based photodynamic therapy - Epidermolysis Bullosa (EB), Epidermolysis Bullosa Dystrophica | Phase 4 | Active not recruiting | Universidade Ceuma | 20 | 2026-01-12 | 2026-07-16 |
| Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types. HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System - Cutis Laxa Facialis, Xeroderma | Phase 4 | Completed | Austin Institute for Clinical Research | 27 | 2023-11-20 | 2024-10-24 |
| Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers 0.9% Sodium Chloride Injection, Lidocaine Injection 2% - Ehlers-Danlos Syndrome, Anesthesia, Local | Phase 4 | Active not recruiting | University of Calgary | 155 | 2022-11-10 | 2024-12-18 |
| Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome Oxygen, Placebo - Ehlers-Danlos Syndrome | Phase 4 | Unknown | Hospital St. Joseph, Marseille, France | 82 | 2022-03-10 | 2022-03-31 |
| Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection - Congenital Ichthyosis | Phase 4 | Unknown | National Medical Research Center for Children's Health, Russian Federation | 50 | 2021-03-01 | 2021-08-09 |
| Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa Vitamin D, Oral nutritional supplement - Bullosa Epidermolysis, Vitamin D Deficiency | Phase 4 | Unknown | National Medical Research Center for Children's Health, Russian Federation | 110 | 2020-11-21 | 2021-12-17 |
| A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain Hemoporfin PDT - Port-wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 40 | 2020-05-27 | 2023-12-20 |
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) Lansoprazole 30mg, Placebo - Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Phase 4 | Unknown | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 20 | 2020-02-04 | 2020-12-09 |
| A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology Haemoblock, Placebo - Vascular Diseases, Vascular Malformation | Phase 4 | Completed | Center for Vascular Pathology, Moscow | 200 | 2020-01-01 | 2021-11-04 |
| Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD) Kybella - Deformity; Skin, Fat Redistribution | Phase 4 | Completed | The Maas Clinic | 37 | 2018-02-20 | 2026-10-19 |
| Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Hemoporfin - Port-Wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 501 | 2017-08-31 | 2023-12-20 |
| A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain Hemoporfin PDT - Port-wine Stain | Phase 4 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 24 | 2017-08-02 | 2020-08-13 |
| A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa Apligraf - Epidermolysis Bullosa, Wound Healing | Phase 4 | Terminated | University Hospital, Basel, Switzerland | 3 | 2012-06-01 | 2015-03-10 |
| Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. Retapamulin Ointment, 1% - Skin Infections, Bacterial | Phase 4 | Completed | GlaxoSmithKline | 60 | 2007-09-01 | 2016-12-28 |
| Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis Azithromycin, Telithromycin - Maxillary Sinusitis | Phase 4 | Terminated | CPL Associates | 192 | 2005-12-01 | 2007-10-31 |
| Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type celiprolol, Control - EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 54 | 2003-10-01 | 2013-01-16 |
| Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa tetracyclin - Epidermolysis Bullosa | Phase 4 | Withdrawn | Rambam Health Care Campus | 2020-10-28 |
Epidermolysis Bullosa (6) · Port-Wine Stain (4) · Ehlers-Danlos Syndrome (3) · Epidermolysis Bullosa Dystrophica (2) · Ichthyosis Vulgaris (2) · Bone Diseases, Metabolic (1) · Burns (1) · Calciphylaxis (1) · Capillary Malformation-Arteriovenous Malformation (1) · Capillary Malformations, Congenital, 1 (1) · Cardiovascular Diseases (1) · Cellulitis (1) · Chromosome 2q31.2 Deletion Syndrome (1) · Colitis, Ulcerative (1)
Congenital Abnormalities (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Skin and Connective Tissue Diseases (20) · Skin Diseases (19) · Genetic Diseases, Inborn (13) · Skin Diseases, Genetic (13) · Connective Tissue Diseases (7) · Skin Diseases, Vesiculobullous (6) · Cardiovascular Diseases (5) · Collagen Diseases (5) · Vascular Diseases (5) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hemorrhagic Disorders (4)
Oxygen (2) · Azithromycin (1) · Celiprolol (1) · Deoxycholic Acid (1) · Dietary Supplements (1) · Lansoprazole (1) · Lidocaine (1) · Sodium Chloride (1) · Tetracycline (1) · Transplantation, Autologous (1) · Ustekinumab (1) · Vitamin D (1) · dupilumab (1) · hematoporphyrin monomethyl ether (1) · secukinumab (1)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (3) · National Medical Research Center for Children's Health, Russian Federation (2) · Abeona Therapeutics, Inc (1) · Assistance Publique - Hôpitaux de Paris (1) · Austin Institute for Clinical Research (1) · CPL Associates (1) · Center for Vascular Pathology, Moscow (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · GlaxoSmithKline (1) · Hospital St. Joseph, Marseille, France (1) · Jay C. Buckey Jr. (1) · Kerecis Ltd. (1) · Rambam Health Care Campus (1) · The Maas Clinic (1) · Universidade Ceuma (1)
United States (5) · China (3) · Russia (3) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Costa Rica (1) · France (1) · Germany (1) · Mexico (1) · Netherlands (1) · South Africa (1) · Spain (1) · Switzerland (1)
Jining Tao (2) · Alexander Plotkin, PhD (1) · Andreas Arnold, MD (1) · Boris Bienvenu (1) · Corey S Maas, M.D. (1) · Dmitry V Romanov, MD (1) · Edward Lain, MD, MBA (1) · Ekaterina M Listovskaya, BSc (1) · Jay Buckey (1) · Jerome J Schentag, Pharm.D. (1) · Joseph Paladino, Pharm.D. (1) · Lin Ma, MD (1) · Satish R Raj, MD MSCI (1)